Choose a language and wait for the translated text.
Shots:
Amplitude and Lilly entered into a strategic research collaboration and licensing agreement to discover and develop trans-amplifying RNA (taRNA) vaccine candidates for infectious diseases. Lilly retains the option to add up to two additional infectious disease targets.
The collaboration combines Amplitude’s proprietary taRNA platform with Lilly’s global development, manufacturing, regulatory, and commercialisation capabilities.
Amplitude will lead taRNA optimisation and selected preclinical research, while Lilly will oversee further development and commercialisation activities
Ref: BioSpace | Image: Amplitude and Lilly | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
The post Amplitude Therapeutics and Eli Lilly Partner to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases appeared first on PharmaShots.
